Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Sintomas da intoxicação inicial de Eucalyptus proporcionados por subdoses de glyphosate aplicadas no caule ou nas folhas

Com o objetivo de avaliar os sintomas de intoxicação causados pela aplicação de glyphosate, foi montado um estudo composto por quatro ensaios com aplicações de glyphosate (360 g e.a. L-1) em eucalipto. Em todos os ensaios, mudas foram transplantadas em vasos de 5,0 L. Nos ensaios 1 e 2, foram aplicados volumes crescentes de solução de glyphosate no caule do eucalipto. No ensaio 1, a solução de 3% (v/v) foi aplicada nos volumes de 0, 1, 5, 10, 20, 40, 80 e 160 µL de calda por planta e, no segundo, a solução de glyphosate a 2% (v/v) foi aplicada nos volumes de 0, 1, 5, 15, 30, 60, 90, 120 e 150 µL de calda por planta. Nos ensaios 3 e 4, foram feitas aplicações de glyphosate sobre as plantas de eucalipto. No ensaio 3, as doses foram de 0, 7,2.10-7, 7,2.10-6, 7,2.10-5, 7,2.10-4, 7,2.10-3, 7,2.10-2, 7,2.10-1, 7,2, 72, 360 e 720 g e.a. de glyphosate ha-1 e, no ensaio 4, de 0, 9, 18, 36, 72, 144, 288, 432, 576, 720, 1.080, 1.440 e 2.160 g e.a. de glyphosate ha-1. Nos quatro ensaios foi utilizado o delineamento DIC, com três repetições. Nas plantas, foram avaliadas a altura, a área foliar e a matéria seca de caule e folhas. Os resultados obtidos foram submetidos a análises de regressão. Quando aplicadas no caule, doses de 40,78 e 51,41 µL de calda por planta de glyphosate a 3 e 2% (v/v), respectivamente, nos ensaios 1 e 2, foram suficientes para redução média de 50% das características estudadas. Nas aplicações sobre as folhas, houve maior sensibilidade das plantas mais desenvolvidas. Para redução média de 50% nas variáveis analisadas, foram necessárias doses de 277,4 e 143,3 g e.a. de glyphosate ha-1 nos ensaios 3 e 4, respectivamente.This work was carried out to evaluate intoxication symptoms caused by glyphosate application. It was constituted by four assays with glyphosate applications (360 g a.e. L-1) on eucalyptus. In all assays, seedlings were transplanted into 5.OL plastic pots. In assays 1 and 2, increasing herbicide volumes were applied on the stem. In the first one, a glyphosate solution of 3% (v/v) was applied at the volumes 0, 1, 5, 10, 20, 40, 80 and 160 µL solution per plant, and in the second, glyphosate solution of 2% (v/v) was applied at volumes 0, 1, 5, 15, 30, 60, 90, 120 and 150 µL solution per plant. In assays 3 and 4, glyphosate was sprayed on the plants. The rates in the third assay were: 0, 7.2 10-7, 7.2 10-6, 7.2 10-5, 7.2 10-4, 7.2 10-3, 7.2 10-2, 7.2 10-1, 7.2, 72, 360 and 720 g a.e. of glyphosate ha 1, and in the fourth assay, the rates were: 0, 9, 18, 36, 72, 144, 288, 432, 576, 720, 1.080, 1.440 and 2.160 g a.e. of glyphosate ha-1. All assays were arranged in a randomized design, with three replications. Height, leaf area, and dry mass of the leaves and stem were evaluated in the plants and the results were submitted to regression analysis. When applied on the stem, doses of 40.78 and 51.41 µL per plant of glyphosate solution, 3 and 2% (v/v), respectively, were sufficient to reduce eucalyptus development in 50%. When applied on the plants, more developed plants showed greater sensitivity.Rates of 277.4 and 143.3 g a.e. ha-1 reduced eucalyptus growth in 50%, in assays 3 and 4, respectively